Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zimlovisertib Phase 2 in RA with Inadequate Response to Methotrexate
NCT02996500Phase 2Completed
- Sponsor
- Pfizer
- Start
- Nov 2016
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 19
01
Overview
Phase 2, randomised, double-blind trial of zimlovisertib in rheumatoid arthritis (RA) (6 arms), sponsored by Pfizer. Primary endpoint: Change From Baseline in the Simplified Disease Activity Index at 12 weeks. Started Nov 2016; status: completed.
02
Drugs
zimlovisertib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02996500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02996500.